Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
- 17 August 2016
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 21 (6) , 460-465
Abstract
Objective: To assess the effects of aripiprazole once-monthly 400 mg (AOM 400) on clinical symptoms and global improvement in schizophrenia after switching from an oral antipsychotic.Methods: In a multicenter, open-label, mirror-image, naturalistic study in patients with schizophrenia (>1 year, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR] criteria), changes in efficacy measures were assessed during prospective treatment (6 months) with AOM 400 after switching from standard-of-care oral antipsychotics. During prospective treatment, patients were cross-titrated to oral aripiprazole monotherapy (1–4) weeks followed by open-label AOM 400 (24 weeks). Mean change from baseline of the open-label AOM 400 phase in Positive and Negative Syndrome Scale (PANSS) scores (total, positive and negative subscales) and Clinical Global Impression–Severity (CGI-S) scores; mean CGI–Improvement (CGI-I) score; and proportion of responders (≥30% decrease from baseline in PANSS total score or CGI-I score of 1 [very much improved] or 2 [much improved]) were assessed.Results: PANSS and CGI-S scores improved from baseline (P<0.0001) and CGI-I demonstrated improvement at all time points. By the end of the study, 49.0% of patients were PANSS or CGI-I responders.Conclusions: In a community setting, patients with schizophrenia who were stabilized at baseline and switched to AOM 400 from oral antipsychotics showed clear improvements in clinical symptoms.Keywords
This publication has 20 references indexed in Scilit:
- A Primer on Effectiveness and Efficacy TrialsClinical and Translational Gastroenterology, 2014
- Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophreniaJournal of Medical Economics, 2013
- Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up studyJournal of Psychiatric Research, 2012
- Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With SchizophreniaThe Journal of Clinical Psychiatry, 2012
- Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting InjectionSchizophrenia Research and Treatment, 2012
- Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting InjectableClinical Drug Investigation, 2012
- A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaBMC Psychiatry, 2012
- The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009Schizophrenia Bulletin, 2009
- The Expert Consensus Guideline SeriesThe Journal of Clinical Psychiatry, 2009
- Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With SchizophreniaPsychiatric Services, 2004